International Immunology, Vol. 16, No. 1, pp. 51-54,
January 2004
© 2004 Japanese Society for Immunology
Paradoxical alteration of acute-phase protein levels in patients with chronic hepatitis C treated with IFN-
2b
1 Third Department of Internal Medicine, Faculty of Medicine, Semmelweis University, Kútvölgyi út 4, 1125 Budapest, Hungary 2 Second Department of Internal Medicine and Gastroenterology, Polyclinic of the Hospitaller Brothers of St John of Good, Frankel Leó út 17-19, 1027 Budapest, Hungary 3 Central Hospital of Ministry of Internal Affairs, Városligeti fasor 9-11, 1071 Budapest, Hungary 4 Third Department of Internal Medicine, Szt László Hospital, Gyáli út 5-7, 1097 Budapest, Hungary 5 First Department of Internal Medicine, University of Pécs, Ifjúság út 13, 7624 Pécs, Hungary 6 St George Hospital Székesfehérvár, Seregélyesi út 3, 8000 Székesfehérvar, Hungary 7 Department of Molecular Diagnostics, National Medical Center, Daróci út 24, 1113 Budapest, Hungary 8 County Hospital, Zalaegerszeg, Zrínyi M. u. 1, 8900 Zalaegerszeg, Hungary 9 Petz A. Hospital, Györ, Vasvári P. u. 2-4, 9024 Györ, Hungary
Correspondence to: L. Kalabay; E-mail: kalasz{at}kut.sote.hu
Transmitting editor: A. Falus
Previously we observed elevation of the serum concentration of two acute-phase protein (AFP) complement components (C9 and C1-inhibitor) in patients with chronic hepatitis C who responded (R) to IFN-
therapy, but not in non-responders (NR). In the present study we investigated the effect of high-dose IFN-
therapy on serum concentrations of two positive [orosomucoid (OROSO) and C-reactive protein (CRP)] and two negative [transferrin (TF) and fetuin/
2HS-glycoprotein (AHSG)] AFP in an outpatient setting. We investigated blood samples of 40 patients with chronic hepatitis C at the onset and at the end of a 3-month treatment with high-dose IFN-
2b (5 MIU/day for 6 weeks, followed by 5 MIU t.i.w.) and of 52 healthy individuals. Serum concentrations of OROSO, TF and AHSG were measured by radial immunodiffusion; CRP levels were determined by immunotubridimetry. Compared to controls, patients with chronic hepatitis C had significantly lower OROSO and CRP, and higher AHSG levels. By the end of treatment, OROSO concentration increased in R (P = 0.0054), but not in NR patients. In contrast, TF levels decreased in R (P = 0.0040), but did not change in NR patients. Similarly, in R patients, AHSG levels tended to decrease (P = 0.0942) following IFN-
treatment. We conclude that the acute-phase reaction is suppressed in patients with chronic hepatitis C that may be potentially related to the responsiveness to IFN-
therapy.
Keywords: chronic hepatitis C, fetuin/
2HS-glycoprotein, IFN-
therapy, orosomucoid, transferrin